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Abstract
The global obesity epidemic has necessitated the search for better intervention strategies including the exploitation of the health benefits of some
gut microbiota and their metabolic products. Therefore, we examined the gut microbial composition and mechanisms of interaction with the
host in relation to homoeostatic energy metabolism and pathophysiology of dysbiosis-induced metabolic inflammation and obesity. We also
discussed the eubiotic, health-promoting effects of probiotics and prebiotics as well as epigenetic modifications associated with gut microbial
dysbiosis and risk of obesity. High-fat/carbohydrate diet programmes the gut microbiota to one predominated by Firmicutes (Clostridium),
Prevotella and Methanobrevibacter but deficient in beneficial genera/species such as Bacteroides, Bifidobacterium, Lactobacillus and
Akkermansia. Altered gut microbiota is associated with decreased expression of SCFA that maintain intestinal epithelial barrier integrity, reduce
bacterial translocation and inflammation and increase expression of hunger-suppressing hormones. Reduced amounts of beneficial micro-
organisms also inhibit fasting-induced adipocyte factor expression leading to dyslipidaemia. A low-grade chronic inflammation (metabolic
endotoxaemia) ensues which culminates in obesity and its co-morbidities. The synergy of high-fat diet and dysbiotic gut microbiota initiates
a recipe that epigenetically programmes the host for increased adiposity and poor glycaemic control. Interestingly, these obesogenic mecha-
nistic pathways that are transmittable from one generation to another can be modulated through the administration of probiotics, prebiotics and
synbiotics. Though the influence of gut microbiota on the risk of obesity and several intervention strategies have been extensively demonstrated
in animal models, application in humans still requires further robust investigation.
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The global epidemic rates of obesity, which almost tripled
between 1975 and 2016(1), could be attributed to increased intake
of unbalanced diet and reduced physical activity(2). There are now
over 1·9 billion (39 % of the global population) overweight adults
in which at least 650 million (13 %) of them are clinically obese.
Similarly, about 41million children under the age of 5 years and
340 million children and adolescents between 5 and 19 years
are either overweight or obese(1). Environmental factors such as
increased high-energy, low-nutrition food consumption and
sedentary lifestyles influence bacterial metabolism including
bacteria in the gastrointestinal tract, that is, gut microbiota, which
harbours over 1014 bacterial cells from the mouth to the colon(3–5).
The number of micro-organisms in the human body is up to
ten times higher than that of human cells(3–5). Though the micro-
bial composition depends on the organ inhabited, the highest
density of microbes is found in the gastrointestinal tract(3–5).
This ‘microbial organ’ constituted by the microbiota contributes
to homoeostasis and influence energy metabolism, insulin sen-
sitivity(6,7) and immunological response(3). After an initial decline
from the mouth (109) to the stomach (103)(3,8) possibly due to
increased acidity, the number of micro-organisms increases
from the proximal small intestine (about 105) to the colon
(about 1012)(3) where there is high density of anaerobes due
to the low O2 tension in this region
(9). Because it contains the
Abbreviations: CD14, cluster of differentiation 14; F:B, Firmicutes:Bacteroidetes; FIAF, fasting-induced adipocyte factor; GLP, glucagon-like peptide;
GPR, G protein-coupled receptor; HNF4α, hepatocyte nuclear factor 4α; LPS, lipopolysaccharide; MB, metabolic bacteraemia; ME, metabolic endotoxaemia;
PYY, peptide YY; TLR4, Toll-like receptor 4.
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highest density of microbes and easily sampled using faeces
as a proxy for colonic microbiota, the colon is the most widely
studied gut site in relation to microbiota composition and risk of
obesity(3). An alteration in the composition of the microbiota
within or on the body is associated with many diseases including
obesity via several mechanisms. Obesity is fundamentally
propagated by a positive energy imbalance, that is, more energy
is being consumed than expended(6,7).
The prevalence of obesity continues to increase despite
sustained efforts to enlighten the public on the risk of developing
chronic adiposity-associated co-morbidities with excessive
increase in body weight and obesity. This global epidemic has
necessitated the search for better intervention strategies includ-
ing the exploitation of the health benefits of some gut microbiota
and their metabolic products(10). In this review, we examined gut
microbial composition and the mechanisms of interaction with
the host in relation to homoeostasis of energy metabolism and
pathophysiology of dysbiosis-induced metabolic inflammation
and obesity. We also described the eubiotic, health-promoting
influences of probiotics, prebiotics, synbiotics and antibiotics
on intestinal microbiota. The role of epigenetic modifications
associated with gut microbial dysbiosis and the risk of obesity
was also discussed. We searched the literature through
PubMed/MEDLINE and Web of Science databases between
November 2018 and July 2019 using words and phrases such
as (but not limited to) ‘gut microbiota and obesity’, ‘gut micro-
biome and obesity’, ‘gut microbiota and energy homeostasis
or energy metabolism’, ‘obesity-associated gut microbiota’,
‘modulation of gut microbiota’, ‘gut microbiota, obesity and
inflammation’. The search included both original research and
review articles involving both humans and animal models
written in English. Though publication dates were not restricted,
articles published within the last two decades and focusing on
the gut microbiota-metabolite profiles and inflammatory
response in relation to obesity were preferred and included after
review/approval by at least two members of the research
team. Furthermore, articles discussing only gut microbiota and
diabetes mellitus or other diseases (apart from obesity) were
excluded.
Microbiota-associated energy harvest
The healthy human gut microbiota consist of over 1000 phylo-
types classified into six bacterial divisions/phyla: Firmicutes,
Bacteroidetes, Proteobacteria, Fusobacteria, Actinobacteria
and Verrucomicrobia(11,12). While earlier mostly cultivation-
dependent studies reported Bifidobacterium and Bacteroides
make up 85–98% of gut microbiota(13), it is currently believed
(using cultivation independent metagenomics technologies) that
the gut microbiota comprise mainly (>90%) Firmicutes and
Bacteroidetes(12,14–17) (Fig. 1), and sometimes Actinobacteria(18).
The changes in gut microbiota associated with obesity are sum-
marised in Table 1(3). The Firmicutes are Gram-positive bacteria
and include Lactobacillus, Mycoplasma, Streptococcus and
Clostridium, while Bacteroidetes, which are Gram-negative bac-
teria, include about twenty genera and species, for example,
Bacteroides thetaiotaomicron(14). These organisms are usually
benign inhabitants of the intestinal ecosystem coexisting with
the host in a commensal and symbiotic relationship. However,
a few can be pathogenic especially when they gain access to
the peritoneal cavity or systemic circulation(14).
Predisposition to increased body fat or obesity is determined
by the Firmicutes:Bacteroidetes (F:B) ratio(17). Obese microbiota
exhibit significantly elevated F:B ratio compared with lean gut
microbiota with preponderance of Bacteroidetes (up to 50 %
more) even when food/energy consumption between the
groups is similar. Obese individuals have shown up to 90 % less
Bacteroidetes and more Firmicutes than lean individuals(17,19).
The composition of Bacteroidetes in obese microbiota is
Fig. 1. Gut microbiota-induced energy utilisation. A shift in the gut microbiota in favour of Firmicutes, for example, with consumption of high-fat/carbohydrate diet
increases energy extraction from the diet with corresponding weight gain and obesity if left uncontrolled. Contrastingly, consumption of diet low in fat and sugar increases
Bacteroidetes dominance, which encourages weight loss by stimulating increased expression of fasting-induced adipocyte factor (FIAF) and subsequent increase in
energy expenditure and reduced fat storage. , Stimulation/increase; , inhibition/decrease.
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increased, while Firmicutes are reduced with corresponding
weight loss by decreasing consumption of high-fat/carbohydrate
diet(19–21). In contrast, with a 209 kJ increase in energy extraction
from the diet, a 20 % rise in Firmicutes and a proportionate
decrease in Bacteroidetes associatedwithweight gain have been
recorded(20). Therefore, an influence of the gut microbiota on
host energy harvest, that is, an obesogenic function associated
with increased Firmicutes and an antiobesogenic function of
Bacteroidetes, was suggested(19,20).
However, these microbiota signatures are not observed in
some cases due to confounding factors that affect the compo-
sition of the gut microbiota including fasting, composition and
energetic content of diet, use of antibiotics(22), age, geographi-
cal location(23), intensity and regularity of exercise(24), genetic,
technical and clinical factors(23). For instance, an increase in
Bacteroidetes over Firmicutes (decreased F:B ratio) was observed
in overweight and obese unrestricted human subjects(24). In
other cases, within the same cohort, differences in gut microbiota
have been observed at the genus and family levels but not
at the phylum level. Recently, a Korean adolescent population
showed higher Bacteroides/Bacteroidaceae in the normal-
weight group, whereas the obese participants had higher
Prevotella/Prevotellaceae. Additionally, the relative abundance
of Firmicutes, Bacteroidetes and Proteobacteria; and the F:B ratio
did not differ significantly(23). Furthermore, although there is an
overall agreed increase in Firmicutes(25), some other studies
have attributed the risk of obesity to decrease in the proportion
of Actinobacteria (Bifidobacterium)(26,27) or Verrucomicrobia
(Akkermansia muciniphila)(28,29) and not the F:B ratio (Table 1).
Hence, the shift in the gut microbiota in relation to changes in
dietary composition could be better interpreted within defined
study populations.
The pathogenesis of obesity is partly mediated by gut micro-
biota(22) (Fig. 1). The gut microbiota is capable of harvesting
(metabolising) energy from the diet, for example, metabolising
(digesting) the otherwise indigestible dietary fibres. Dietary
fibres (polysaccharides and oligosaccharides) as well as proteins,
peptides and glycoprotein are converted into products that are
readily absorbed by the host such as SCFA – acetate, propionate
and butyrate(18). SCFA contribute about 10% of daily energy
requirement and are accountable for almost 75 % of energy
metabolism in the colonic epithelium(18,30,31). Therefore, the rate
of SCFA metabolism can determine the direction of host energy
balance(18).
There are also methanogenic Archaea (Methanobrevibacter
smithii) that oxidise (recycle) H2 produced by bacterial species
by combining it with carbon dioxide. Fermentation of polysac-
charides by bacterial species such as Prevotella is enhanced
by increased H2 utilisation by methanogenic Archaea. This H2
transfer between bacterial and archaeal species favours
increased energetic uptake by obese individuals(18,30,32),
although the utility of Archaea as a potential biomarker of obesity
has been queried(24). However, the literature evidence suggests
that the gut microbiota determine the differences in the effi-
ciency of energy extraction from diet and energy metabolism
in the muscle, liver and adipose tissue(22,30) (Fig. 1). Therefore,
obesity occurs when there is a positive energy imbalance occa-
sioned by increased energy consumption than expended(31).
Furthermore, metagenomics studies reveal association of
obese microbiota (high F:B ratio) with increased starch, galac-
tose and butyrate metabolism due to the high presence of
α-amylases and amylomaltases(21). There was significantly
higher acetate and butyrate production and reduced energy
in faecal matter in the obese group compared with their lean
counterparts. This indicates a positive relationship between
elevated F:B ratio and increased energy harvest from nutrients,
lipogenesis and obesity.
Effect of gut microbiota metabolites on host’s energy
balance
The gut microbiota interacts with the intestinal epithelial cells
through several mechanisms including production of metabolic
end products such as SCFA, for example, acetate, butyrate and
propionate. As previously stated, these are fermentation prod-
ucts of the degradation of non-digestible carbohydrate and
non-carbohydrate substrates in the large intestine. As no bacteria
has the capacity to hydrolyse all nutrients and produce all metab-
olites observed in the gut lumen, there is metabolic synergy
among the bacterial community, that is, the entire community
collaborate to produce the physiological relationship with the
host cells(30). Dysregulation of the physiological and biochemical
interaction between the host and gut microbiota is characteristic
of the obese state(11).
SCFA are absorbed by the intestinal cells by passive diffusion
and mono-carboxylic acid transporters, for example, monocar-
boxylate transporter 1. Apart from being themajor energy source
for colonic epithelial cells(31), SCFA also perform other metabolic
roles. For instance, acetate is a precursor for cholesterol or fatty
acid synthesis (lipogenesis), for example, de novo synthesis
of lipids in liver(18); propionate is a substrate necessary for
gluconeogenesis(22) and reduces food intake and cholesterol
synthesis(18); while butyrate is involved in cell growth and differ-
entiation(30). Butyrate also protects against diet-induced obesity
without causing hypophagia, reduces insulin insensitivity in
mice and has obesity-associated anti-inflammatory and anti-
cancer properties in humans, as well as increases leptin gene
expression(18).
Acetate and butyrate are also able to promote mitochondrial
fatty acid oxidation and energy expenditure via the activation
of 5 0-AMP-activated protein kinase. 5 0-AMP-activated protein
Table 1. Obesity-associated changes in gut microbiota*








Euryarchaeota (domain archaea) Methanobrevibacter ↑
↑, Increase; ↓, decrease.
* Adapted from Kobyliak et al.(3).
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kinase phosphorylates and inhibits acetyl-CoA carboxylase,
which reduces malonyl-CoA synthesis(33). Decreased malonyl-
CoA activates carnitine:palmitoyl-CoA transferase-1, which
enhances uptake and oxidation of long-chain acyl-CoA fatty
acids in the mitochondria of liver and muscles leading to weight
loss and increase in cholesterol and TAG levels(5,30,33).
Acetate and butyrate also influence intestinal epithelial
barrier function by reducing epithelial permeability. They stimu-
late goblet cells to produce mucin containing mucus, increase
the expression of tight junction proteins, for example, zonula
occludens-1, zonulin, occludin and claudin, thereby protecting
the epithelial cells and decreasing intestinal permeability. This
prevents the translocation of intestinal bacteria and lipopolysac-
charide (LPS)-induced inflammation(5,30).
Furthermore, the SCFA prevent inflammation by inhibiting
NF-κB-mediated expression of TNF-α, IL-6, IL-12, etc. (Fig. 2)
and increase the expression of IL-10. The SCFA perform this
anti-inflammatory action by binding to G protein-coupled recep-
tor 41 and 43 (GPR41 and GPR43) expressed in intestinal
epithelial cells. Acetate shows preference for GPR43 through
which its anti-inflammatory action is achieved(30).
The SCFA also partly mediate the expression and activity
of anorectic (hunger-suppressing) hormones such as glucagon-
like peptide-1 (GLP-1, produced by colonic L-cells), peptide
YY (PYY, produced by ileal and colonic cells) and adipose
tissue-derived leptin. These hormones act on the hypothalamus
to promote satiety and reduce food intake. SCFA are believed to
mediate these processes via GPR41(30).
Obesogenic metabolic inflammation
Obesity is characterised by a chronic low-grade inflammation
propagated by proinflammatory mediators such as TNF-α, IL-1
and IL-6 released by adipocytes. These cytokines stimulate the
release of more cytokines and chemokines, and lipogenesis
by acting on adipocytes in a paracrine and/or autocrine fashion.
The gut epithelium provides the largest body surface for
host–microbial interaction promoting tolerance to commensals
(Fig. 2), while preventing the growth and proliferation of patho-
gens via optimal immune responses(3). Gram-negative intestinal
bacteria such as Prevotellaceae (high in obese individuals)(3,18)
continuously release LPS that along with the bacteria stimulates
strong immune response by binding to Toll-like receptor 4
(TLR4) and cluster of differentiation 14 (CD14) receptors on innate
immune cells(34), after translocation into the circulation (Fig. 2).
The translocation is aided by increased intestinal permeability
due to deficient epithelial barrier associated with decreased
SCFA production(5). A chronic low-level systemic accumulation
of bacteria and LPS results in metabolic bacteraemia (MB)(35)
Fig. 2. Obesogenic intestinal host–microbial interaction. In healthy condition, the commensal microbes express reduced levels of pathogen-associated molecular
pattern (PAMP) and decreased NF-κB activation due to reduced ubiquitination and proteasomal degradation of IκB (inhibitor of NF-κB). More so, the intestinal epithelial
cells express normal levels of Toll-like receptors (TLR) 3 and 5, reduced levels of TLR 2 and 4, and increased levels of TLR-inhibiting peptide (TOLLIP)(3). Both processes
ensure a symbiotic relationship and immune tolerance. However, a breach in this relationship, for example, lipopolysaccharide (LPS) translocation can trigger an
LPS-induced metabolic inflammation associated with obesity. TLR4 dimerises after binding and activation by LPS. This eventually results in transcription of proinflam-
matory genes and cytokine secretion by NF-κB (via activation of IKK (IκB kinase) complex) and activator protein-1 (AP-1) (via activation of c-Jun N-terminal kinase (JNK)
and mitogen-activated protein kinase (p38)). These intracellular signalling pathways are mediated by adapter molecules – myeloid differentiation primary response
protein 88 (MyD88), andMyD88 adapter-like protein (MAL) or Toll-IL-1 receptor adapter protein (TIRAP); and signalling transduction proteins including IL-1R-associated
kinase (IRAK); TNF receptor-associated factor-6 (TRAF6); mitogen-activated protein kinase kinase (MAP2K); transforming growth factor β-activated kinase-1 (TAK1);
and TAK1-binding protein (TAB1).
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and endotoxaemia (ME)(34), respectively – proinflammatory proc-
esses characteristic of obesity and other metabolic syndrome
phenotypes(36).
High-fat diet increases adherence of Gram-negative bacteria
to the gut mucosa and enhances translocation of the bacteria into
circulation and sequestration in the mesenteric lymph due to
phagocytosis(11). LPS is also absorbed by enterocytes into the
circulation with chylomicrons (fat globules)(37) and transported
through the lymphatic fluid to the liver and adipose tissue. ME
stimulates obesity and insulin insensitivity(34). This was observed
in normal diet-fed germ-free mice infused with LPS that devel-
oped ME symptoms and elevated body fat/weight gain similar
to their counterparts on high-fat diet. High-fat diet increases
LPS translocation and circulation levels up to 2–3-fold but
significantly (10–50 times) lower than septicaemic and infection
levels(34,38,39). The LPS-inducedmetabolic changes are accompa-
nied by reduction of Bacteroides and Bifidobacterium that
reduce intestinal LPS levels in mice and improve mucosal barrier
function(40,41).Clostridium coccoides belonging to the Firmicutes
phyla (Gram positive) was also reduced(34).
Interestingly, deletion of CD14 delays these obesogenic
actions of LPS and high-fat diet(34), which resumed perhaps
due to the interaction of LPS with TLR4(31). NEFA can also bind
TLR4 to activate innate immune cells(42) leading to the release of
cytokines. However, this high-fat diet-induced effect does not
occur in the absence of CD14 and TLR4. Absence of CD14 and
TLR4 confers some protection against the metabolic, inflamma-
tory and obesogenic effects of high-fat diet or LPS infusion(11,34).
Hence, CD14 appears to set the threshold at which metabolic
diseases occur(34). Bacterial translocation and MB are also
prevented in high-fat diet-fed mice lacking nucleotide-binding
oligomerisation domain-containing protein 1 or CD14(35).
Further reading on the host–microbiota interaction, that is,
the mechanisms associated with gut epithelial barrier function
and integrity, and ME/MB, obesity and insulin resistance can
be found in the reviews by Saad et al.(5), Shen et al.(11) and
Carvalho & Saad(30).
Inhibition of angiopoietin-like protein 4
Angiopoietin-like protein 4 also known as fasting-induced
adipocyte factor (FIAF) or PPARγ angiopoietin-related protein
or hepatic fibrinogen/angiopoietin-related protein is a cell
signalling glycoprotein hormone (about 50 kDa) and adipocyto-
kine produced by white adipose tissue, liver, heart, skeletal
muscle and intestines(31,43–46). FIAF inhibits lipoprotein lipase
activity and stimulates white adipose tissue lipolysis (Fig. 3), with
increased circulating levels observed during fasting(43,45).
Lipoprotein lipase hydrolyses lipoprotein-associated TAG to
NEFA, which are re-esterified into TAG and stored as fat in
peripheral white adipose tissue (lipogenesis). FIAF stimulates
fatty acid oxidation and fat mobilisation leading to a reduction
in adipose tissue mass. Increased FIAF expression increases
plasma levels of TAG, NEFA, glycerol, HDL-cholesterol and total
cholesterol(44). FIAF may also decrease plasma glucose level,
return hyperglycaemia to normal level and attenuate hyperinsu-
linaemia and glucose intolerance(47). Fatty acids stimulate
expression of FIAF in mice and humans (especially in fasting,
prolong energetic restriction and exercise) by activating
PPARα (liver, small intestine), γ (adipose tissue, colon) and δ
(heart, skeletal muscle, macrophages)(45), whereas insulin sup-
presses FIAF expression(48) (Fig. 3). The contrasting action of
fasting and insulin on FIAF regulation may account for the shift
in energy utilisation from fatty acids derived from lipoprotein
after a meal to NEFA during fasting(45). The glucocorticoids-
induced flux of TAG fromwhite adipose tissue to the liver is also
mediated by FIAF(43).
Decreased FIAF expression has been observed in germ-free
mice colonised by normal caecal microbiota with a correspond-
ing increase in adipocyte lipoprotein function and total fat mass
content by 122 and 57 %, respectively(49). Though the exact
micro-organisms were not identified, stimulation of lipogenesis
(deposition of TAG in adipocytes) via microbiota-induced
suppression of FIAF expression was implicated(49). Bacterial
fermentation products such as SCFA have also shown ability
to promote increased FIAF expression through PPARγ in colon
cells(30). FIAF is a potent regulator of lipid metabolism and adi-
posity, dysregulation of which might result in dyslipidaemia(44).
Further reading on the physiological role of FIAF and other
angiopoetin-like proteins on lipid/NEFA metabolism can be
found in Mattijssen & Kersten(45).
Modulation of gut microbiota
The global burden of obesity has triggered the search for suitable
bespoke intervention strategies including the exploration of the
eubiosis and health-promoting effects of some gut microbiota
and their metabolic products(10). A food design strategy modify-
ing themicrobiota combinedwith altered food intake rather than
medical(30,50) or surgery-based(30,51) interventions appears more
cost-effective and readily accessible by a larger population.
Probiotics
As a consequence of the relationship between gut microbiota
and obesity, modulation of the microbiota by probiotics could
promote weight loss, reduce BMI and fat percentage(10), hence,
be employed in treatment of obesity or as a prophylactic
treatment for those at risk. Probiotics are viable micro-organisms
that have health-promoting effects on the host when adminis-
tered in adequate amounts as food ingredients(11,22,52). The
effect of Lactobacillus, Bifidobacterium and Saccharomyces
on weight loss and/or fat deposition in overweight adults has
been reported(52,53). More than 60 % of the studies demonstrated
Lactobacillus species-dependent decrease in body weight and/
or body fat. For example, weight loss is enhanced by
Lactobacillus gasseri and Lactobacillus amylovorus; hypoener-
getic diet combined with Lactobacillus plantarum and
Lactobacillus rhamnosus; L. plantarum combined with
Lactobacillus curvatus; and combining Lactobacillus acidophi-
lus, Lactobacillus casei and phenolic compounds.
Forty-three overweight humans who consumed 200 g of
fermented milk containing L. gasseri per d for 12 weeks
experienced significant reduction in abdominal visceral and
subcutaneous fat, body weight, BMI and waist and hip
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circumference compared with those that had unsupplemented
fermented milk(54). Supplementation of high-fat diet with
Lactobacillus paracasei F19 and Bifidobacterium lactis, but
not B. thetaiotaomicron, up-regulates FIAF expression and
concomitant anti-obesogenic benefit to the host(31,50), for exam-
ple, reducing serum TAG levels and alleviating fat deposition in
liver(55). Similarly, mice supplementation with Bifidobacterium
infantis and Bifidobacterium bifidum for about a month
showed significantly reduced gut endotoxin levels with no
increase in IL-6, TNF-α, INF-γ(40). Treatment of high-fat diet-fed
mice with Bifidobacterium animalis subsp. Lactis 420 improves
overall inflammatory and metabolic status by reversing/prevent-
ing bacterial translocation through the intestinal epithelium(35).
Additionally, treatment with mucin-degrading A. muciniphila
was associated with improved metabolic profile achieved by
reversing fat deposition, ME, adipose tissue inflammation and
insulin resistance induced by high-fat diet. Treatment with
A.muciniphila or its extracellular vesicles also increases intestinal
levels of endocannabinoids that enhance gut epithelial barrier
function by increasing expression of occludin and decreasing
intestinal permeability, as well as controls inflammation and gut
peptide secretion(29,56).
Yeast probiotics such as Saccharomyces boulardii also
improve the microbiota-metabolic profiles of genetically obese
and diabeticmice to onewith reduced Firmicutes and increased
Bacteroidetes with a corresponding decrease in fat mass and
circulating inflammatory mediators(57). In addition, multispe-
cies probiotics such as VSL#3 also influence (restore) gut micro-
biota profile and promote epithelial tight junction integrity
and anti-inflammation(30,58), thereby preventing fat accumula-
tion and weight gain(22,29). VSL#3 is a commercial probiotic
mixture of lactobacilli (L. casei, L. plantarum, L. acidophilus
and Lactobacillus delbrueckii subsp. bulgaricus); bifidobac-
teria (Bifidobacterium longum, Bifidobacterium breve and
B. infantis) and Streptococcus (Streptococcus salivarius
subsp. thermophilus)(11,58).
Fig. 3. Regulation of fat metabolism and storage by fasting-induced adipocyte factor (FIAF). By activating PPAR on tissues associated with energy utilisation and fat
storage, fasting, fatty acids and bacterial fermentation products such as SCFA increase the expression of FIAF. FIAF is a potent lipoprotein lipase inhibitor and stimulates
fatty acid oxidation, metabolism and lipolysis. This results in increased plasma levels of TAG, NEFA, glycerol and cholesterol culminating in depletion of fat storage and
hence decreased body weight and obesity. FIAF also decreases plasma glucose levels, hyperinsulinaemia and glucose intolerance, while insulin inhibits its expression.
ANGPTL4, angiopoietin-like protein 4. , Stimulation/increase; , inhibition/decrease.
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In contrast to the health-promoting (antiobesogenic) effects
of probiotics, some studies have reported no health benefit or
even obesogenic effects associatedwith probiotics. For instance,
enhanced weight gain observed in livestock that were fed huge
amounts of probiotics has stimulated speculations that the
obesity pandemic in humans may be associated with high
consumption of foods enriched with probiotic bacteria(59).
Two meta-analyses also suggested that probiotics may promote
weight gain in children and undernourished individuals while
promoting weight loss in adults and obese individuals(60,61).
These discrepancies have been attributed to differences in
probiotic bacterial strain administered as well as age and base-
line body weight of the host(22). Therefore, more comprehensive
randomised controlled trials are required to ascertain the efficacy
of probiotics in the management of obesity locally or globally.
Prebiotics
Prebiotics are non-digestible food ingredients (usually polysac-
charides) capable of selectively stimulating growth and/or
activity of microbiota especially lactobacilli and bifidobacteria,
thereby providing health-promoting effects on host energy
balance(62,63). They modify the microbiota to mitigate the risk
of dysbiosis and associated gut and systemic pathologies, that
is, they restore and/or maintain eubiosis or normobiosis(62).
Most fermentable dietary fibres particularly non-digestible
oligosaccharides such as fructo-oligosaccharides (e.g. inulin),
galacto-oligosaccharides and resistant starch(63) that occur in
several foods(64) have shown capacity to alter gut microbiota.
They also increase satiation by up-regulating GLP-1 and PYY
and decrease secretion of ghrelin, thereby reducing food
intake(11,30,65,66). An example is the weight loss, decreased
ghrelin expression, increase in PYY levels, low energy intake,
low plasma glucose and insulin levels experienced by forty-
eight adults with BMI > 25 kg/m2 who received 21 g/d of
oligofructose for 12 weeks(7). Similarly, obese pre-menopausal
women who ingested oligofructose-rich syrup (0·14 g fructo-
oligosaccharides/kg per d) for 120 d experienced a dramatic
weight loss (up to 15 kg) during the study accompanied by
decreased fasting insulin and LDL-cholesterol levels(67).
Prebiotics are fermented to metabolically active SCFA by
bacteria in the large intestine. It is believed that the antiobeso-
genic effects of prebiotics are mediated, at least partly, by the
SCFA including acetate, propionate and butyrate(11,30). They also
enhance gut mucosal integrity and barrier function by increasing
Bifidobacterium population(66,68), which is known to produce
butyrate(51).
Synbiotics and antibiotics
For a more beneficial effect, a combination of probiotics and pre-
biotics,which is termed synbiotics, has beenemployed. For exam-
ple, combining oligofructose-enriched inulin, Lactobacillus
rhammnosus and B. lactis, altered the microbiota in favour
of Lactobacillus and Bifidobacterium at the expense of
Clostridium perfringens(69). This appears to be more efficacious
than either probiotics or prebiotics singly and has been demon-
strated in in vitro studies(70) but requires further investigation in
humans(71).
Additionally, broad-spectrum antibiotic therapy has been
employed inmice to reduce intestinal permeability by increasing
tight junction protein expression, reduce LPS-induced inflamma-
tion and improve obesity-induced insulin resistance in the liver,
muscle and adipose tissue. These effects are plausibly achieved
through the reduction of circulating levels of LPS and TLR4
activation. Portal acetate levels, which activate 5 0-AMP-activated
protein kinase, fatty acid oxidation and energy expenditure
(Fig. 3), also increase with antibiotic treatment. However, antibi-
otic resistance, ability to alter commensal bacterial community
and the possible association of chronic low-dose antibiotic
use and weight gain have hindered successful translation to
humans(30).
Themechanisms underpinning this probiotic-inducedmodu-
lation of gut microbiota promoting weight loss and reduced
fat mass include decreasing gut permeability by maintaining
epithelial cell tight junctions, preventing translocation of whole
bacteria, their products and metabolites thereby decreasing
LPS-induced inflammation. The reduced inflammation enhances
leptin and insulin sensitivity in the hypothalamus that improves
satiety and glucose tolerance. Improved hypothalamic insulin
sensitivity combined with increased concentrations of GLP-1
and PYY leads to increased satiety and reduced food intake.
Reduced energy consumption and elevated FIAF expression
encourage weight loss and reduced fat deposition(30).
Bariatric surgery has also been shown to increase gut
microbial diversity by reducing the relative abundance of
Firmicutes and increasing the abundance of Bacteroidetes, that
is, decreased F:B ratio. This was reported in a recent systematic
review that included studies employing the two main variants
of bariatric surgery, that is, Roux-en-Y gastric bypass and the
laparoscopic sleeve gastrectomy(72).
Diet-microbiota-dependent epigenetic changes
An epigenetic trait is a ‘stably heritable phenotype resulting from
changes in a chromosome without alterations in the DNA
sequence’(73). Hence, epigenetics could be defined as the study
of heritable phenotype alterations that occur without changes
in DNA sequence(74). These changes are triggered by factors
including diet, ageing, drugs, environmental chemicals, etc.(73).
The possibility of epigenetic alterations underlying certain host
responses to changes in the gut microbiome has been high-
lighted. Dysbiosis alters both the transcriptome and proteome
of intestinal epithelium(75–77). Gut microbiota regulates gene
expression through DNA methylation in intestinal epithelium
independent of DNA methyltransferase. The DNA methylation
changes can be reproduced by faecal transplantation(78).
Chromatin structure in intestinal intraepithelial lymphocytes(79)
and several host tissues is also modified by gut microbiota in
a diet-dependent manner(80). The result is alterations in gene
transcription/expression and host physiology(80).
Obesogenic diet programmes the gut microbiota to one
deficient in bifidobacteria (that elaborates SCFA particularly
butyrate, improves tight junction protein expression, maintains
epithelial barrier integrity and reduces proinflammatory cyto-
kine expression in mucus)(81). Reduced amounts of the
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beneficial micro-organisms also encourage ME and MB(11,34,35).
A low-grade chronic inflammation ensues which is a hallmark
of obesity and related diseases such as diabetes(5,35,82) and
cancer(77,83). Both high-fat diet and a dysbiotic gut microbiota
are required to epigenetically programme the host for obesity,
diabetes and colorectal cancer. This is mediated by the bacterial
metabolites produced from the host diet that are capable of alter-
ing gene expression(5,77,84).
Microbiota metabolite-induced alteration in gene expression
was observed to be regulated by hepatocyte nuclear factor
4α (HNF4α), a nuclear receptor capable of activating or
repressing gene transcription(77). It is plausible that fatty acids
produced from bacterial metabolism of high-fat diet bind to
HNF4α because lipids have been identified as HNF4α-binding
ligands(85). Obesity is associated with down-regulation of genes
enriched in HNF4α binding sites with slightly higher levels of
HNF4α at such sites in obese mice. Animals that received obeso-
genic diet and microbiota showed down-regulation of genes
gaining HNF4α binding(77).
Mother-to-child transmission of obesity
An offspring could be a product of the combination of the
dietary patterns of both the offspring and mother. Prenatal
exposure to adverse (obesogenic) microbiota-metabolic envi-
ronment may increase the offspring’s susceptibility to obesity
in postnatal life(79). This has been demonstrated by examining
maternal mechanisms regulating developmental programming
of offspring obesity in rats(31,86,87). Maternal obese microbiomial-
metabolite phenotype can programme the offspring’s risk of
obesity. The ability of prebiotics to encourage the growth and
metabolism of distinct health-promoting gut microbiota was
explored to mitigate the intergenerational transmission of obesity
to offspring(86).
Pregnant Sprague–Dawley rats became obese after 2 weeks
of feeding on high-fat/sucrose diet. This diet-induced obesity
was associated with lower relative abundance of faecal
Bifidobacterium sp. and Lactobacillus and higher Clostridium
and Methanobrevibacter sp.(86,87). These changes are consistent
with the increased energy harvest and obesity associated with
high F:B ratio, and the contrasting improved intestinal epithelial
barrier integrity promoted by Bifidobacterium supplementa-
tion(31). Diet-induced obese dams also showed higher blood
glucose, plasma insulin, fasting plasma leptin (produced in pro-
portion to fat mass) and lower PYY. Furthermore, they showed
increased levels of ketone bodies and metabolites involved
in lipid metabolism. Elevated branched chain amino acids
(associatedwith increased insulin resistance) and decreased glu-
cogenic amino acids were also identified in the obese dams(86).
Expectedly, supplementing the maternal high-fat/sucrose
diet with oligofructose prebiotic increased the relative abun-
dance of Bifidobacterium sp. and Bacteroides sp. and reduced
Clostridium and Methanobrevibacter sp. There were also
increased plasma levels of PYY, GLP-1 and GLP-2. Their serum
metabolite profiles were characterised by elevated levels
of gut microbial metabolites (propionate, acetate, butyrate,
isobutyrate, formate, etc.) and markers of increased insulin
sensitivity (myo-inositol). Amino acids involved in arginine
metabolism that are associated with improved pregnancy out-
comes and reduced offspring adiposity were also identified.
Consequently, there was a reduction in energy intake and
maternal gestational weight gain. Therefore, maternal prebiotic
supplementation in pregnancy and lactation encourages the
preponderance of antiobesogenic microbiota associated
with reduced fat mass, weight loss and improved insulin
sensitivity(86).
In the offspring, maternal oligofructose supplementation
was associated with lower fat mass, percentage body fat and
fasting plasma glucose but similar insulin concentrations
compared with offspring from non-supplemented dams.
Maternal adiposity correlated with offspring adiposity.
Maternally supplemented offspring also displayed higher levels
of satiety hormones – PYY, GLP-1 and GLP-2. These metabolic
and hormonal/behavioural changes suggest decreased energy
intake, improved glycaemic control and reduced risk of insulin
resistance and diabetes in postnatal life of offspring born to
prebiotic-supplemented dams(86). The reduced adiposity
observed in offspring of prebiotic-supplemented dams was
attributed to the distinct maternal metabolite signature.
Similarly, children born to mothers who consumed a probiotic
strain (L. rhamnosus GG) continuously from 4 weeks before
delivery to 6 months after delivery were prevented from exces-
sive weight gain in their first decade of life(88). Apart from
improving our understanding of the maternal mechanisms
associated with the developmental programming of offspring
obesity, these observations highlight a potential strategy to
improve maternal and offspring metabolic adaptive outcomes
in pregnancy(86,87).
Conclusion
High-fat/carbohydrate diet programmes the gut microbiota to
one deficient in Bacteroides, Bifidobacterium, Lactobacillus
and Akkermansia and rich in Firmicutes (Clostridium),
Prevotella and Methanobrevibacter. These alterations in bacter-
ial species composition are associated with decreased expres-
sion of SCFA that improve tight junction protein expression,
maintain intestinal epithelial barrier integrity, reduce bacterial
translocation and proinflammatory cytokine expression(81) and
increase expression of hunger-suppressing hormones. Reduced
amounts of the beneficial micro-organisms also encourage
ME and MB(11,34,35) and reduced FIAF expression leading to dys-
lipidaemia. A low-grade chronic inflammation ensues that culmi-
nate in obesity and associated diseases such as diabetes(5,35,82)
and cancer(77,83). The synergy of high-fat diet and dysbiotic gut
microbiota creates a recipe that epigenetically programmes
the host for increased adiposity and poor glycaemic control.
Interestingly, these obesogenic mechanistic pathways that are
sometimes transmitted from one generation to another can be
modulated through the administration of probiotics, prebiotics
and synbiotics. Though the influence of gut microbiota on the
risk of obesity and several intervention strategies have been
extensively demonstrated in animal models, application in
humans still requires further robust investigation.
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